# Evidence Map: <br> Reporting of results by sex or gender in randomized controlled trials with women Veteran participants 2008-2018 



Elisheva Danan, MD, MPH<br>Center for Care Delivery and Outcomes Research<br>Minneapolis VA Health Care System

## Acknowledgements

Co-authors:

- Kristen Ullman, MPH
- Ruth Klap, PhD
- Elizabeth Yano, PhD, MSPH
- Erin Krebs, MD, MPH


## Disclosures

I have no financial relationships to disclose.

The views expressed in this presentation are those of the authors and do not represent the views of the VA or the U.S. Government.

Article
Evidence Map: Reporting of Results by Sex or Gender in
Randomized, Controlled Trials with Women Veteran
Participants (2008 to 2018)
Elisheva R. Danan, MD, MPH ${ }^{\text {a,b,* }}$, Kristen Ullman, MPH ${ }^{\text {a }}$, Ruth S. Klap, PhD ${ }^{\text {c }}$, Elizabeth M. Yano, PhD, MSPH ${ }^{\text {c,d }}$, Erin E. Krebs, MD, MPH ${ }^{\text {a,b }}$
${ }^{2}$ VA HSRED Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota
${ }^{\text {b }}$ Department of Medicine, University of Minnes ota Medical School Minneapolis, Minnesota
${ }^{c}$ VA HSRED Center for the Study of Healthcare Innovation, Implementation \& Policy. VA Greater Los Ang eles Healthcare System, Los Angeles,
California
${ }^{\text {d }}$ Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, California
Artide history: Received 24 August 2018; Received in revised form 8 April 2019; Accepted 17 April 2019

## Click here for link to Full Article Online

## Poll Question \#1

Let's get to know who's in the audience:
Select your main role(s)!
$\square$ Physician
$\square$ Nurse
$\square$ Research PI
$\square$ Research study staff
$\square$ Veteran
$\square$ Other (VA personnel, student, etc)

## Overview

Background

Methods

Results

Key Findings and Conclusions

## Poll Question \#2

What's the difference between Sex and Gender?
$\square$ There's a difference?
$\square$ It's simple: Sex refers to biological attributes, while Gender is a sociocultural construct
$\square$ Actually it's a lot more complicated than that

## Definitions

Sex = biological attributes

Gender = psychosocial or sociocultural

Do Sex and Gender matter for Health Research? including physical features, chromosomes, gene expression, hormones and anatomy.


Have you considered the possibilities?
Learn more: www.clhr-Irsc.gc.ca/shapingsclence.html

# Sex and Gender influences on pharmacological response 

Sex: pharmacokinetics, pharmacodynamics
Table 1. Some difference between men and

| women. |  |  |
| :--- | :---: | :---: |
| Differences | XX | + |
| Birth and adult weight | + |  |
| Infant mortality | + | + |
| Height | Peripheral | + |
| Muscle | + |  |
| Fat | + | + |
| Distribution of fat | + | + |
| Total water | + | + |
| Intracellular water | + |  |
| Extracellular water | + |  |
| Plasma | + |  |
| Heart frequency | + |  |
| Average organ flow | + |  |
| Glomerular filtration rate | + |  |
| Gastric pH (acidity) | + |  |
| Gastrointestinal mobility | + |  |
| Gastric emptying | + |  |
| Acetylcholine esterase | + |  |
| Catechol-O-methyl <br> transferase | + |  |
| CyP2D6 | + |  |
| CYP3A4 | + |  |
| QTc interval | + |  |



Figure 1. Factors influencing adherence.
Gender: access to care, other health behaviors (ie, smoking), placebo effect, medication adherence, education, socio-economic status, patient-physician dyad

Franconi F and Campesi I, Sex and gender influences on pharmacological response: an overview, Expert Review of Clinical Pharmacology, May 2014

# Sex and Gender reporting in health research over time 

- In 2001, the US government reported that 8 out of 10 drugs removed from the market in preceding years had more significant adverse effects for women than men
- The NIH and the National Academy of Medicine (formerly IOM) have called for increased participation of women in medical research
- Now close to 50\% female in NIH funded trials


## Women Veterans

10\% of all living Veterans are women $16 \%$ by 2040

7\% of VA patients are women
$175 \%$ increase in 15 years!



Younger than men

More diverse
42\% racial/ethnic minority

## Previous Review

- Reviewed ALL the women Veterans' health research from 2008-2015
- Excluded studies that didn't explicitly report results for women
- Over 350 studies excluded!
- Major gap: Need to improve reporting of results by sex or gender

An Evidence Map of the Women Veterans' Health Research Literature (2008-2015)
Elsheva R. Danan, MD, MPH ${ }^{12}$, Etin E. Kebss, MD, MPH ${ }^{1.2}$, Kistine Enssud, MD, MPH ${ }^{1,2}$, Eva Koeller, BA', Roderick MacDonald MS', Ina Velasquez, MS', Nancy Greer, PhD', and Ilmothy J. WIIt, MD, MPH ${ }^{\prime 2}$
 Uriverity of Mrresola Mocical Schod. Mrreopoi. M. USA.

BACKGROUND:Women comprise a growing proportion of Veterans secking care at Veterans Affars (VN) heallhcare faclities. VA intiatives have accelerated changes in services for female Veterans, yet the corresponding liecrature VA Women's Health Sericers and the VA Women's Health AA Women's Health Services and the UA Women's Health Research Network requested an updated
to facilitate policy and research planning.
METHODS:The Minneapolls VA Evidence-based Synthesis Program performed a systematic search of research rdated to famale Veterans' heath published from 2008 through 2015. We extracted study characteristics including healthcare tople, design, sample ste and proportion femak, research setting, and funding source. We created an evidence map by organting and presenting results within and across healthcare topks, and describing patterns, strengths, and graps.
RESULTS: We identified 2276 abstracts and assessed each for relevance. We excluded 1092 abstracts and 440 toduded artikles 208 4579 were relatad to mental holth particilaty post-traumatic stress disonder 171 articles) military semal trauma ( 37 artides), and substance abuse (20 artikled. The number of articles addressing VA priorty topk areas increased over tume, including reproductive health, healthcare organtation and delivery: access and utflization, and post-dqployment health. Three or Ewer artides addressed each of the common chronic diseases: diabictes hypertension, depression, or andety. Nearty 400 artikles f90na ued an obervational destgn. Elight artides (299 described randomized trials.
CONCLUSIONS: Our evidence map summarizes pattems, progress, and growth in the female Veterans' health tal health make up the majority of research. A focus on primary care delkery ovar clinical topics in primary care and a lack of sec-spectic results for studes that the chide men and women have contributed to mes man and womon have contributed
addressing common

CALL FOR SUBMISSIONS
Despite saving in or alongside the US military since the Revolutionary War, women have experienced unequal accers Vetons Affir, (VA) benfis and fw womm used va Werese Aysa) prior the arly 1990. ${ }^{1}$ In the suba . 3 years, clinical, rescarch, and policy in itiatives have sought to mprove the quality and accessibility of evidence-basod health care for famake Veterans. ${ }^{2}$ Today, women are the fastest. growing population of US Veterans receiving VA healthcare. ${ }^{3}$ Whan the literature related to famale Veterans' health and healthcare was last reviewed in $2008,^{4-6}$ the authors ancounered a rapidly emerging field of rescarch. They described growth in rescarch rdated to access, utilvaton, and organizafional quality, but identifed gaps in research related to chronic physical and mental health conditions, complex combinations of disease. prognancy and aging, traumatic brain injury, comanagad mental and physical preventive care, and post ployment trassitional halth Subsequently, the VA wonn's halth landecape has changed subtantially. In 2008 , th
 tod to ovence clinical initativas, such as the provision of , comprchonsive womon's haltheare (including gencral an ander-spacific care) at a single site fiom a single provider. The VA Womon's Health Research Natwork (WHRN) was creatad in 2010 to fill knowlodge gaps in the evidance base deatad to female Vetanas' health and healthcare.' Based in art on the resuls of the previous review, the WHRN prion itized research on six key topic areas: (1) mental halth, (2) pimary care and prevention, (3) reproductive health, (4) complex chronic conditions aging and long-term care,(S)acoss to care and rural healh, and (6) nostriner__n

FOR SUBMISSIONS

To a Special Supplement to Women's Health Issues
SexJGender Differences in VA Clinical and Health Services Research

## Objectives

Overall: Evaluate attention to sex and gender
in randomized controlled trials (RCTs) with women Veterans over the past decade (2008-18)

## Overview

Background

Methods

Results

Key Findings and Conclusions

# Systematic Review vs. Evidence Map 



Miake-Lye et al. Systematic Reviews (2016) 5:28 DOI 10.1186/s13643-016-0204-x

Annals of Internal Medicine Research and Reporting Methods
PRISMA Extension for Scoping Reviews (PRISMA-SCR): Checklist and Explanation
Andrea C. Tricco, PhD, MSc; Erin Lillie, MSc; Wasifa Zarin, MPH; Kelly K. O’Brien, PhD, BScPT; Heather Colquhoun, PhD; Danielle Levac, PhD, MSc, BSCPT; David Moher, PhD, MSC; Micah D.J. Peters, PhD, MA(Q); Tanya Horsley, PhD; Laura Weeks, PhD; Susanne Hempel, PhD; Elie A. AkI, MD, PhD, MPH; Christine Chang, MD, MPH; Jessie McGowan, PhD; Lesley Stewart, PhD, MSc; Lisa Hartling, PhD, MSc, BScPT; Adrian Aldcroft, BA(Hons), BEd; Michael G. Wilson, PhD; Chantelle Garritty, MSc; Simon Lewin, PhD; Christina M. Godfrey, PhD, RN; Marilyn T. Macdonald, PhD, MSN; Etienne V. Langlois, PhD; Karla Soares-Weiser, MD, PhD; Jo Moriarty, MA; Tammy Clifford, PhD, MSc; Özge Tunçalp, MD, PhD, MPH; and Sharon E. Straus, MD, MSc

# What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products 

## Search strategy

MEDLINE search:
MeSH terms: Women; Women's health; Women's Health Services; Transgendered persons; Veterans; Veterans health; Hospitals, Veterans

- English language
- 2008 to present

Exclusion Criteria:
Not related to health/healthcare
Does not include Female Veterans
Not a randomized controlled trial

## Key questions



# Best practices for Sex and Gender 

Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use

Shirin Heidari ${ }^{1}$, Thomas F. Babor ${ }^{2 *}$, Paola De Castro ${ }^{3}$, Sera Tort ${ }^{4}$ and Mirjam Curno ${ }^{5}$

- Created criteria for appraisal of attention sex and gender
- Intended to be descriptive

Table 1 Sex and Gender Equity in Research (SAGER) guidelines General principles

- Authors should use the terms sex and gender carefully in order to avoid confusing both terms.
- Where the subjects of research comprise organisms capable of differentiation by sex, the research should be designed and conducted in a way that can reveal sex-related differences in the results, even if these were not initially expected.
- Where subjects can also be differentiated by gender (shaped by social and cultural circumstances), the research should be conducted similarly at this additional level of distinction

Pecommendations per section of the article
Title and If only one sex is included in the study, or if the results abstract of the study are to be applied to only one sex or gender, the title and the abstract should specify the sex of animals or any cells, tissues and other material derived from these and the sex and gender of human participants.

Introduction Authors should report, where relevant, whether sex and/ or gender differences may be expected.

Methods Authors should report how sex and gender were taken into account in the design of the study, whether they ensured adequate representation of males and females, and justify the reasons for any exclusion of males or females.

Results Where appropriate, data should be routinely presented disaggregated by sex and gender. Sex-and gender-based analyses should be reported regardless of positive or negative outcome. In clinical trials, data on withdrawals and dropouts should also be reported disaggregated by sex.

Discussion The potential implications of sex and gender on the study results and analyses should be discussed. If a sex and gender analysis was not conducted, the rationale should be given. Authors should further discuss the implications of the lack of such analysis on the interpretation of the results.

## Overview

Background

Methods

Results

Key Findings and Conclusions


Evidence Map: RCTs with veteran participants, by proportion women, reporting of results by sex or gender, and publication year


# Q1 Results: Compare characteristics or RCTs that do or do not report sex/gender results 

| Trial characteristics | Women and men veteran participants |  |
| :---: | :---: | :---: |
|  | NO results by sex or gender $(n=30)$ | Results by sex or gende $(n=10)$ |
| nrandomired dariticipants |  |  |
|  |  |  |

## Trial characteristics

## Women and men

 veteran participantsResults by sex or gender ( $n=10$ )
$n(\%)$ or median(IQR)

Health care topic
 Health care delivery Access, Utilization, PDH
Study location(s)

| Single site <br> Multi-site |
| ---: |
| VA Cooperative study |
| WH PBRN study |
| Non-VA or Community based |

Intervention type
Pharmacologic
Behavioral
Health services
Device or Physical treatment

# Q2 Results: Attention to Sex and Gender among those that DID report 




## Overview

Background

Methods

Results

Key Findings and Conclusions

## Participation of women Veterans

Studies that reported sex/gender results were:

- larger (n=344 vs. 126)
- included a higher proportion of women (17 vs. 11\%)

Women are $10 \%$ of living Veterans; $7 \%$ of VA users

- only 1 of 13 trials with <10\% women reported sex/gender results

VA ORD requires "special efforts... to include women Veterans"

- Since 2013, the number of women and men enrolled must be reported on ClinicalTrials.gov
- The WH PBRN may help improve recruitment


## Reporting sex/gender results

25\% of studies reported sex/gender results

- Similar to reviews of non-Veteran RCTs (13-48\% women)
- Funders/Regulators (NIH/FDA) and Journals (ICMJE/Consort) can try to raise this proportion

Only 1 of 11 pharmacologic/device studies presented sex/gender results

CSP study at
12 VAMCs
$N=304$

297 men
7 women (2\%)

M.A. Raskind, E.R. Peskind, B. Chow, C. Harris,* A. Davis-Karim, H.A. Holmes, K.L. Hart, M. McFall, T.A. Mellman,

## Improved attention to sex/gender

- An interaction test is great, but it's not enough!

Power calculation
False positives/negatives

- Why do you think there might be a relationship between sex/gender and the intervention?
- Provide full results disaggregated by sex, regardless of interaction test results


## Poll Question:

Have you ever received training on sex and gender research and analyses?
$\square$ Yes, I'm an expert - ask me anything!
$\square$ Just a bit, I need more training and experience
$\square$ Never - this is the first I've heard of it!

## Opportunities to improve

VA Women's Health
Research Network:
Click here to learn more about the VA WHRN


## Click here for NIH resources

The 4 Cs of Studying Sex to Strengthen Science


号


[^0]
## Limitations

Search criteria specific to women
Likely overestimates the proportion that report sex/gender

Limited to published data and online supplements
Missed some data on ClinicalTrials.gov

Only included RCTs
Lots of single-arm pilots and implementation/evaluation projects

## Conclusions

Women Veterans are increasingly participating in clinical trials

Reporting of results by sex/gender remains infrequent

Even those that do report sex/gender results often omit key information

Improving attention to sex/gender for research that includes women veterans will improve the applicability of knowledge gained from veteran research to the care of women

## Questions?

Elisheva Danan, MD, MPH
elizabeth.danan@va.gov


[^0]:    Online Training Modules:
    Integrating Sex \& Gender in Health Research
    $\square$ Course 1: Sex and Gender in Biomedical Research Start course More intormation

